Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Dimed Distribuidora de Medicamentos's Enterprise Value for the quarter that ended in Jun. 2026 was R$2,750 Mil.
Dimed Distribuidora de Medicamentos's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$318 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos EV-to-EBIT Related Terms
Dimed Distribuidora de Medicamentos EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos EV-to-EBIT Chart
BSP:PNVL3 vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Dimed Distribuidora de Medicamentos's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dimed Distribuidora de Medicamentos EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dimed Distribuidora de Medicamentos's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Dimed Distribuidora de Medicamentos's EV-to-EBIT falls into.
Dimed Distribuidora de Medicamentos's current Enterprise Value is R$2,794 Mil.
Dimed Distribuidora de Medicamentos's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was R$318 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dimed Distribuidora de Medicamentos (BSP:PNVL3) has a EV-to-EBIT of 8.77 as of Aug. 20, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dimed Distribuidora de Medicamentos and its competitors. This is 54% below median its historical median of 18.96. Over the past decade, Dimed Distribuidora de Medicamentos' EV-to-EBIT has ranged from 8.55 to 52.94. According to the industry distribution chart, Dimed Distribuidora de Medicamentos ranks #167 out of 687 companies in the Drug Manufacturers industry, placing it in the top 24.3%.
Is Dimed Distribuidora de Medicamentos' EV-to-EBIT too high?
Dimed Distribuidora de Medicamentos' current EV-to-EBIT of 8.77 is 54% below median its 10-year median of 18.96. Over the past 10 years, this metric has ranged from a low of 8.55 to a high of 52.94. The Drug Manufacturers industry median EV-to-EBIT is 15.81. Dimed Distribuidora de Medicamentos' value of 8.77 is 44.5% below this industry median. Based on the distribution chart, Dimed Distribuidora de Medicamentos ranks #167 out of 687 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Dimed Distribuidora de Medicamentos has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dimed Distribuidora de Medicamentos' EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Dimed Distribuidora de Medicamentos ranks #167 out of 687 companies for EV-to-EBIT. This places Dimed Distribuidora de Medicamentos in the top 24% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.81. Dimed Distribuidora de Medicamentos' value of 8.77 is 44.5% below this benchmark. Historically, Dimed Distribuidora de Medicamentos' own EV-to-EBIT has ranged from 8.55 to 52.94 over the past decade. While the company's 10-year median is 18.96 vs. the industry median of 15.81, Dimed Distribuidora de Medicamentos has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.81, based on 687 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Dimed Distribuidora de Medicamentos's current EV-to-EBIT of 8.77 is 44.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Dimed Distribuidora de Medicamentos and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Dimed Distribuidora de Medicamentos's current EV-to-EBIT is 8.77, which is 54% below median its own 10-year median of 18.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dimed Distribuidora de Medicamentos stock overvalued right now?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos (BSP:PNVL3) is currently considered Modestly Undervalued. The stock's GF Value™ is R$13.19, compared to a current price of R$11.28 — trading 14.5% below its estimated fair value. The current EV-to-EBIT is 8.77, which is 54% below median its 10-year median of 18.96 and 44.5% below the Drug Manufacturers industry median of 15.81. Dimed Distribuidora de Medicamentos' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Dimed Distribuidora de Medicamentos (BSP:PNVL3), the current EV-to-EBIT is 8.77 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Dimed Distribuidora de Medicamentos (BSP:PNVL3) Overvalued in 2026?
Based on GuruFocus' analysis, Dimed Distribuidora de Medicamentos stock appears to be undervalued.
The current stock price of R$11.28 is trading 14.5% below its estimated GF Value™ of R$13.19.
GuruFocus considers Dimed Distribuidora de Medicamentos to be Modestly Undervalued.
Key valuation signals for BSP:PNVL3:
EV-to-EBIT: 8.77 (54% below median its 10-year median of 18.96)
GF Value™: R$13.19 vs. price of R$11.28 (14.5% below fair value)
Industry Position: 44.5% below the Drug Manufacturers median (#167 of 687)
No single metric tells the full story. See the BSP:PNVL3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Dimed SA Distribuidora de Medicamentos is engaged in the sale of medicines, perfumery, personal care and beauty products, cosmetics and dermocosmetics. It has single reportable segment that is, The Retail segment. The Retail segment has 556 stores that sell more than 15,000 items among drugs and personal care and beauty products. In addition to adding divisions of cosmetics, drugs and food, Lifar is responsible for the production of brands in Brazil, as well as products of its own brand Panvel.
87GF Score
Get the complete analysis for BSP:PNVL3
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:PNVL3 has been successfully added to your 
